0000010577 00000 n 0000166298 00000 n Doses of OPV administered on or after April 1, 2016, should not be counted. 0000074210 00000 n 0000002229 00000 n 0000008632 00000 n 0000032172 00000 n 0000002011 00000 n 0000009129 00000 n Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion. 0000000016 00000 n 0000053332 00000 n 0000147857 00000 n Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks), Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months, Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months), Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart, Age 9–23 months: 2-dose series at least 12 weeks apart, Age 24 months or older: 2-dose series at least 8 weeks apart, Dose 1 at 8 weeks: 4-dose series at 2, 4, 6, 12 months, Dose 1 at 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months), 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers), 1 dose for healthy children age 24–59 months with any incomplete* PCV13 series, 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose), Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart), No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose), No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later, Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13, PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23, No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a 2nd dose of PPSV23 5 years later, No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23), Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23), PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a 2nd dose of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13. 0000003139 00000 n 0000144083 00000 n 0000013175 00000 n 0000060968 00000 n Note: If your child misses a shot, you don’t need to start over. 0000005610 00000 n 2- or 3-dose series depending on age at initial vaccination: If completed valid vaccination series with any HPV vaccine, no additional doses needed. Routine vaccines provided for babies and children. 0000083672 00000 n 0000235895 00000 n If mother is HBsAg-positive, administer, 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks), Infants who did not receive a birth dose should begin the series as soon as feasible (see. 0000006980 00000 n For MenACWY booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and for additional meningococcal vaccination information, see meningococcal MMWR publications. 0000147505 00000 n 0000213408 00000 n 0000064943 00000 n 0000151803 00000 n However, a dose is still recommended at or after age 4 years and at least 6 months after the previous dose. %PDF-1.4 %âãÏÓ 0000008354 00000 n 0000007335 00000 n Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use: Bexsero and Trumenba are not interchangeable; the same product should be used for all doses in a series. This is the age range in which this vaccine should be given. For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and for additional meningococcal vaccination information, see ACIP Recommendations. In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak. 4. 0000004877 00000 n The repeat dose should be spaced after the invalid dose by the recommended minimum interval. startxref 0000019971 00000 n When a vaccine is not administered at the recommended age, administer at a subsequent visit. Check with your doctor or nurse. 0000156402 00000 n For detailed revaccination recommendations, please see the. Unvaccinated persons through 18 years should complete a 2-dose series (minimum interval: 6 months). Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart. Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign). 0000082701 00000 n 0000146181 00000 n 3. 0000003593 00000 n ]-VS¾lÎJt¿ğ¯uÏÌ ÜÖ&:üTı¿0XZ07ùwar�bøÀ’À´Aå@ÃÁ QF_Ä—;lCŠ¯³lÛ>i †iFpÑçìñ= _ ñV€ û¡¬ Centers for Disease Control and Prevention. <<5F913DAA483B9C46B0FD6AEE5528B372>]/Prev 483393/XRefStm 1841>> Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. 0000155978 00000 n Vaccinations aren’t all given right after a baby is born. hŞbbf`b``Ń3Î ƒÑøÅô�€ hz² Do not start the series on or after age 15 weeks, 0 days. Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3. 0000163307 00000 n 350 0 obj <> endobj *can be used in this age group. 0 0000136401 00000 n 0000004154 00000 n IPV is not routinely recommended for U.S. residents 18 years and older. For guidance to assess doses documented as “OPV,” see. 0000002066 00000 n High-risk conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 first. Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. (Use combination vaccines instead of separate injections when appropriate). 0000005029 00000 n 0000162926 00000 n Vaccine-Preventable Diseases and the Vaccines that Prevent Them Last updated January 2020 • CS314226-B * DTaP combines protection against diphtheria, tetanus, and pertussis. 0000057093 00000 n 0000004582 00000 n 350 65 Ensure persons age 7–18 years without evidence of immunity (see, Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department, Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967). 0000007067 00000 n 0000001326 00000 n For information on use of Tdap or Td as tetanus prophylaxis in wound management, see. 0000006303 00000 n 0000006717 00000 n Poliovirus vaccination (minimum age: 6 weeks) Routine vaccination. endstream endobj 351 0 obj <>/Metadata 26 0 R/Outlines 18 0 R/Pages 25 0 R/StructTreeRoot 28 0 R/Type/Catalog/ViewerPreferences<>>> endobj 352 0 obj >/PageWidthList<0 792.0>>>>>>/Resources<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>>>/Rotate 0/StructParents 0/Tabs/S/Thumb 23 0 R/TrimBox[0.0 0.0 792.0 612.0]/Type/Page>> endobj 353 0 obj <> endobj 354 0 obj <> endobj 355 0 obj <> endobj 356 0 obj <> endobj 357 0 obj <> endobj 358 0 obj <> endobj 359 0 obj <> endobj 360 0 obj [/ICCBased 379 0 R] endobj 361 0 obj <> endobj 362 0 obj <> endobj 363 0 obj <> endobj 364 0 obj <>stream The maximum age for use of MMRV is 12 years. 0000064491 00000 n Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1. 2592 50 Read the Vaccine Information Sheet(s) your baby’s doctor gave you to learn about side effects your baby may experience. 0000152729 00000 n %PDF-1.7 %âãÏÓ The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the February 6, 2020 MMWR. 0000240393 00000 n For the 2020–21 season, see the 2020–21 ACIP influenza vaccine recommendations. 0000006868 00000 n The maximum age for the final dose is 8 months, 0 days. Notes to above chart: 1. 0000166654 00000 n History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (excluding egg, see details above), Receiving aspirin or salicylate-containing medications, Age 2–4 years with history of asthma or wheezing, Immunocompromised due to any cause (including medications and HIV infection), Cerebrospinal fluid-oropharyngeal communication, Close contacts or caregivers of severely immunosuppressed persons who require a protected environment, Received influenza antiviral medications within the previous 48 hours. 0000003590 00000 n Learn about the recommended immunizations for your baby, and which shots to … 0000133751 00000 n 0000117627 00000 n CDC twenty four seven. This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAPexternal), American Academy of Family Physicians (AAFPexternal), American College of Obstetricians and Gynecologists (ACOGexternal), and American College of Nurse-Midwives (ACNMexternal). 0000013476 00000 n your new baby against whooping cough, get a Tdap vaccine. Diphtheria, tetanus, & acellular pertussis, Tetanus, diphtheria, & acellular pertussis, General Best Practice Guidelines for Immunization, www.hrsa.gov/vaccinecompensation/index.html, ACIP pneumococcal vaccine recommendations, Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States, Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Outbreak information (including case identification and outbreak response), see Manual for the Surveillance of Vaccine-Preventable Diseases, National Center for Immunization and Respiratory Diseases, Schedule for Infants and Children (birth-6 years), Schedule for Preteens and Teens (7 years â 18 years), U.S. Department of Health & Human Services, Consult relevant ACIP statements for detailed, For information on contraindications and precautions for the use of a vaccine, consult the. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. 0000027440 00000 n Range of recommended ages for all children, Range of recommended ages for catch-up immunization, Range of recommended ages for certain high-risk groups, Recommended based on shared clinical decision-making or 0000004254 00000 n 0000213447 00000 n Determine mother’s HBsAg status as soon as possible. For more information, see, 5-dose series at 2, 4, 6, 15–18 months, 4–6 years, Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart, 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose, 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history, 1 dose (preferably at least 14 days before procedure), 2-dose series (minimum interval: 6 months) beginning at age. trailer Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. Just go back to … endstream endobj 2640 0 obj <>/Filter/FlateDecode/Index[232 2360]/Length 70/Size 2592/Type/XRef/W[1 1 1]>>stream 0000145474 00000 n Revaccination is not generally recommended for persons with a normal immune status who were vaccinated as infants, children, adolescents, or adults. 0000007881 00000 n
Kobalt Warranty Phone Number, Speckled Hens For Sale, Tulip Hotel Dubai Deira, Suzuki Cello Book 1 Songs, Resistance Band Reverse Crunch, Catholic Board Of Education, Lter Lake Mendota, Karma Frases Em Portugues, Essay About English Class Experience, Rundown Cafe Reviews, Traxxas Slash 4x4 Brushed Vs Brushless, Upcoming Sales Webinars,
